Sequella is a private, clinical-stage pharmaceutical company that addresses the challenge of antibiotic-resistant bacterial diseases by discovery, development, and commercialization of first-in-class antibiotics with novel mechanisms of action.
Our lead drug candidate identified from our current >150,000 proprietary compound library, SQ109, is in Phase 2 clinical trials for treatment of both tuberculosis (TB) and gastritis (Helicobacter pylori infections), diseases complicated by growing resistance to existing drugs.
In 2013, we acquired a new clinical-stage (Phase 2) oxazolidinone, sutezolid, for treatment of TB and other resistant bacterial diseases. We also have a vigorous research program to develop novel antibiotics that target the enzyme translocase-1, an essential enzyme in all bacteria.
Our product portfolio addresses global health threats with significant market opportunity in disease areas of known or suspected infectious etiology:
* TB (Mycobacterium tuberculosis)
* Duodenal ulcers (Helicobacter pylori)
* Gastric carcinomas (Helicobacter pylori)
* CDI (Clostridium difficile)
* Crohn’s Disease (Mycobacterium avium paratuberculosis)
* Chagas Disease (Trypanosoma cruzi)
Company Details
- Employees
- 6
- Founded
- -
- Phone
- 3017627778
- ma****@****lla.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- sequella.com
Sequella, Inc. Questions
Sequella, Inc.'s helpline number is 3017627778
Sequella, Inc.'s website is sequella.com
Sequella, Inc.'s LinkedIn profile is https://www.linkedin.com/company/sequella-inc.
Sequella, Inc. has
6 employees.
View email and phone details for 6
employees at Sequella, Inc..
Sequella, Inc.'s industry is
Biotechnology Research
Sequella, Inc.'s top competitors are
Fina Biosolutions Llc,
Tailored Therapeutics,
Moderna,
Salus Discovery,
Community Brands,
Mplexity,
Ocms Bio,
The 90-10 Institute,
Oncosting,
Capital Biolabs.
Sequella, Inc.'s support email address is mail@sequella.com
Sequella, Inc.'s categories are Biotechnology Research
Sequella, Inc.'s founding year is 1997
